Pfaltz & Bauer

Pfaltz & Bauer is a well-established supplier of research and fine chemicals, known for providing rare and hard-to-find products to researchers and manufacturers worldwide. Founded in 1900, the company has a long-standing reputation in the chemical industry.

Product Range:

The company offers a comprehensive catalog of over 25,000 fine and specialty chemicals, catering to research, laboratory, and manufacturing needs. Their "Molecular Mall" features over 600 unique chemicals exclusive to Pfaltz & Bauer.

Facilities and Capabilities:

Pfaltz & Bauer operates a 62,000 square foot facility in the northeastern United States, encompassing production, warehousing, and office spaces. This facility allows them to analyze and package orders in requested quantities immediately prior to shipment. They also offer inventory storage, accommodating quantities from milligrams to multiple drums, to fulfill blanket orders.

Browse Pfaltz & Bauer Products

(+) & (-) beta-Pinene 95%

SKU: P19710-01|Size: 100 mL

(+) (-) -a-2,4,5,7-Tetranitro-9-fluorenylideneaminooxypropionic acid (not optically active)

SKU: T08228|Size: 250 mg

(+) -1,4-Di-o-mesyl-2,3-o-isopropylidenethreitol

SKU: D33610|Size: 1 g

(+) -2 3-O-Isopropylidene-L-threitol 97%

SKU: I10230-01|Size: 1 g

(+) -2 3-o-Benzylidene-D-threitol 99%

SKU: B07700|Size: 1 g

(+) -3-Methyladipic acid

SKU: M10400|Size: 1 g

(+) -3-Methylcyclohexanone 97%

SKU: M15000-01|Size: 1 g

(+) -Arabinogalactan from larch wood

SKU: A35040-01|Size: 25 g

(+) -Catechin hydrate 95%

SKU: C05820-01|Size: 1 g

(+) -Chelidonine

SKU: C07530|Size: 100 mg

(+) -Cinchonine 98%

SKU: C22390-01|Size: 25 g

(+) -DIOP 98%

SKU: D48715-01|Size: 50 mg

(+) -Dimethyl-2 3-O-isopropylidene-D-tartrate 97%

SKU: D41720-01|Size: 1 g

(+) -Pulegone

SKU: P28920-01|Size: 5 g

(+) -Styrene oxide 97%

SKU: S10125-01|Size: 1 g

(+) -Usnic acid 98%

SKU: U01600-01|Size: 5 g

(+) -a-Methoxy-a-trifluoromethylphenylacetic acid 99%

SKU: M09818-01|Size: 250 mg

(+) -a-Pinene 98%

SKU: P19690-01|Size: 10 g

(+) Quinidine anhydrous

SKU: Q00330-01|Size: 5 g

(+/-) -1,3-Butanediol 99%

SKU: B25920-01|Size: 100 mL

(+/-) -2,2-Dimethyl-1,3-dioxolane-4-methanol 97%

SKU: D39750-01|Size: 100 g

(+/-) -Anabasine Dipicrate

SKU: A31990|Size: 500 mg

(+/-) Adenosine 3'-phosphoric acid from yeast

SKU: A11540-01|Size: 1 g

(+/-) trans-1,2-Diaminocyclohexane 99%

SKU: D04405-01|Size: 10 mL

(-) -1,4-Dithio-L-threitol 98%

SKU: D54760|Size: 500 mg

(-) -2 3-O-Benzylidene-L-threitol 95%

SKU: B07702-01|Size: 1 g

(-) -2,3, O-Isopropylidene-D-threitol 98%

SKU: I10220-01|Size: 1 g

(-) -DIOP 97%

SKU: D48720-01|Size: 250 mg

(-) -Dimethyl-2 3-O-Isopropylidene-L-Tartrate 97%

SKU: D41725-01|Size: 5 mL

(-) -Sparteine sulfate anhydrous 95%

SKU: S08060-01|Size: 250 mg

(-) -Usnic acid 97%

SKU: U01620|Size: 1 g

(-) -a-Cedrene

SKU: C05915-01|Size: 250 g

(-) -a-Methoxy-a-trifluoromethylphenylacetic acid 98%

SKU: M09819-01|Size: 250 mg

(-) -a-Pinene 98%

SKU: P19680-01|Size: 500 g

(1,2-Dibromoethyl) benzene

SKU: D09670-01|Size: 25 g

(1R) - (-) -1-Phenyl-1 2-Ethanediol 99%

SKU: P11445-01|Size: 250 mg

(1R) - (-) -Camphorquinone 95%

SKU: C02175-01|Size: 1 g

(1S) - (+) -Camphorquinone 99%

SKU: C02185|Size: 5 g

(1S,2S) -bis (4-Chlorophenyl) ethane-1,2-diamine 98%

SKU: B12710-01|Size: 100 mg

(2,5-Dihydroxyphenyl) acetic acid 95%

SKU: D30290-01|Size: 1 g

(2,5-Dimethoxyphenyl) acetic acid 97%

SKU: D34730-01|Size: 5 g

(2-Bromoethyl) benzene 98%

SKU: B20940-01|Size: 100 g

(2-Bromoethyl) trimethylammonium bromide

SKU: B21090-01|Size: 25 g

(2-Chlorethyl) trimethylammonium chloride 98% - Carc.

SKU: C12625-01|Size: 5 g

(2-Octadecyloxy) pyridine

SKU: O00525|Size: 1 g

(2R,3R) - (+) -Tartaric acid

SKU: T00300-01|Size: 500 g

(2S 3R) - (+) -N-Benzoylthreonine methyl ester

SKU: B05662-01|Size: 1 g

(2S 4S) -4- (Diphenylphosphino) -2- (diphenylphosphinomethyl) pyrrolidine

SKU: D51845|Size: 25 mg

(2S,3S) - (+) -2,3-Butanediol 97%

SKU: B25943-01|Size: 500 mg

(2S,3S) - (-) -Tartaric acid

SKU: T00320-01|Size: 100 g

(3,3,3-Trifluoropropyl) methyldichlorosilane 97%

SKU: T23985|Size: 10 g

(3,3,3-Trifluoropropyl) methyldimethoxysilane 97%

SKU: T23987-01|Size: 5 g

(3,3,3-Trifluoropropyl) methylsiloxanes 97%

SKU: T23990-01|Size: 5 g

(3,3,3-Trifluoropropyl) trichlorosilane 97%

SKU: T23995-01|Size: 5 g

(3,4-Dimethoxyphenyl) acetic acid 98%

SKU: D34740-01|Size: 25 g

(3-Aminopropyl) triethoxysilane 97%

SKU: A28190-01|Size: 100 g

(3-Bromopropyl) triphenylphosphonium bromide 98%

SKU: B24491-01|Size: 5 g

(3-Glycidoxypropyl) bis (trimethylsiloxy) methylsilane 97%

SKU: G03455|Size: 10 g

(4-Carboxybutyl) triphenylphosphonium bromide 98%

SKU: C05065-01|Size: 25 g

(4-Chloro-2-methylphenoxy) acetic acid 93%

SKU: C15020-01|Size: 500 g

(4R,5R) - (+) -1,4-Di-O-tosyl-2,3, O-isopropylidene-D-threitol 98%

SKU: D55205-01|Size: 1 g

(4R,5S) -1,5-Dimethyl-4-phenyl-2-imidazolidone 97%

SKU: D44030|Size: 1 g

(5-Hexenyl) dimethylchlorosilane 97%

SKU: H05860-01|Size: 10 g

(Benzimidazolyl) propionic Acid

SKU: B02720|Size: 5 g

(Carbethoxyethylidene) triphenylphosphorane 96%

SKU: C03040-01|Size: 10 g

(Carbethoxymethyl) triphenylphosphonium Bromide 98%

SKU: C03230-01|Size: 25 g

(Carbethoxymethylene) triphenylphosphorane

SKU: C03180-01|Size: 10 g

(Chloromethyl) triphenylphosphonium chloride 97%

SKU: C15330-01|Size: 5 g

(Cyanomethylphenethyl) trimethoxysilane Mixed Isomers 97%

SKU: C28920|Size: 2 g

(Diethylenetrinitrilo) pentaacetic acid 97%

SKU: D22590-01|Size: 250 g

(Dimethylamino) acetone 98%

SKU: D35470-01|Size: 1 g

(Dodecylbenzyl) trimethylammonium Chloride Tech

SKU: D56380-01|Size: 25 g

(Ethylenedinitrilo) tetraacetic Acid Copper Disodium Salt

SKU: E08820-01|Size: 25 g

(Ethylenedinitrilo) tetraacetic acid 99%

SKU: E08800-01|Size: 100 g

(Ethylenedinitrilo) tetraacetic acid dicalcium salt

SKU: E08830|Size: 1 g

(Ethylenedinitrilo) tetraacetic acid dipotassium salt dihydrate

SKU: E08840-01|Size: 100 g

(Ethylenedinitrilo) tetraacetic acid ferric sodium salt

SKU: E08855|Size: 100 g

(Ethylenedinitrilo) tetraacetic acid magnesium disodium salt solution containing 2.5% chelated magnesium

SKU: E08858-01|Size: 100 g

(Ethylenedinitrilo) tetraacetic acid tripotassium salt, 50% aqueous solution

SKU: E08880-01|Size: 100 g

(Ethylenedinitrilo) tetraacetic acid zinc disodium salt 98%

SKU: E08895-01|Size: 25 g

(Ethylenedinitrilotetraacetic acid) tetrasodium salt dihydrate

SKU: E08870-01|Size: 250 g

(Ferrocenylmethyl) trimethylammonium iodide 99%

SKU: F01051-01|Size: 1 g

(Heptadecafluoro-1,1,2,2-tetrahydrodecyl) -1-trichlorosilane 97%

SKU: H00856-01|Size: 1 g

(Heptadecafluoro-1,1,2,2-tetrahydrodecyl) -1-triethoxysilane 97%

SKU: H00858-01|Size: 5 g

(Methoxymethyl) triphenylphosphonium chloride

SKU: M08378-01|Size: 25 g

(N, N-Diethyl-3-aminopropyl) trimethoxysilane 98%

SKU: D20890-01|Size: 25 g

(R) (+) -N, N-Dimethyl-alpha-phenethylamine

SKU: D43542-01|Size: 1 g

(R) (-) -2-Pentanol

SKU: P04183|Size: 500 mg

(R) - (+) -1-Phenylpropylamine

SKU: P15135-01|Size: 1 g

(R) - (+) -2-Chloropropionic acid 98%

SKU: C18572-01|Size: 1 g

(R) - (-) -2,2-Dimethyl-1,3-dioxolane-4-methanol 98%

SKU: D39752-01|Size: 1 g

(R) - (-) -2-Aminoheptane 97%

SKU: A22393|Size: 1 g

(R) - (-) -2-Phenylbutyric acid 98%

SKU: P10003-01|Size: 1 g

(R) - (-) -2-Phenylpropionic acid

SKU: P15043-01|Size: 250 mg

(R) - (-) -sec-Butanol 99%

SKU: B26257-01|Size: 1 g

(R) -1,2-Epoxyheptane

SKU: E01400-01|Size: 250 mg

(R) -1,2-Epoxytridecane

SKU: E01535|Size: 1 mg

(R) -1-Phenylethanol 95%

SKU: P06582-01|Size: 5 g

(R) -1-Phenylethanol 97%

SKU: P11463-01|Size: 5 g

(R) -Rhododendrol chiral 97%

SKU: R01650-01|Size: 25 mg

Recent Breakthroughs

Magnetic-aminopropyltriethoxysilane-sulfanilamide: a new functional sorbent for selective preconcentration of sulfonylurea antidiabetic drugs in biological samples.

Ulusoy S, İrem Altunbaş Ş, Gürbüzer A, Polat Ü, İbrahim Ulusoy H.

Analyst

PMID:41804642

Free PMC article

A highly selective and sensitive analytical strategy was established for the trace quantification of two oral antidiabetic drugs, gliclazide (GLZ) and glimepiride (GLM). The procedure integrates magnetic solid-phase extraction (MSPE) with high-performance liquid chromatography coupled to diode array detection (HPLC-DAD). In this approach, a newly engineered magnetic-aminopropyltriethoxysilane-sulfanilamide (Fe 3 O 4 @APTES-sulfanilamide) was synthesized and utilized as an innovative adsorbent. Sulfanilamide as a functional molecule on the surface has been used for the first time in this study. The hybrid structure, consisting of a Fe 3 O 4 magnetic core and a sulfanilamide-functionalized silane shell, provides strong binding affinity toward sulfonylurea compounds through synergistic hydrogen bonding and π-π interactions. Optimization studies were carried out to achieve the best extraction efficiency by adjusting experimental variables such as solution pH, adsorption and desorption times, and solvent composition. Under the final working conditions (pH 6.0; desorption with an acetonitrile-methanol mixture), both target analytes were effectively preconcentrated prior to chromatographic determination. Separation was accomplished using an isocratic elution system containing 10% methanol, 40% phosphate buffer (pH 3.0), and 50% acetonitrile, with UV detection at 219 and 256 nm. The developed protocol demonstrated excellent linearity, remarkable enrichment factors, and very low detection limits. Precision studies yielded RSD values below 3.5% ( n = 3, 100 ng mL -1 ). The reliability of the proposed method was further validated by its successful application to both synthetic and human urine samples, giving satisfactory recovery results. This newly designed Fe 3 O 4 @APTES-sulfanilamide -based MSPE coupled with HPLC-DAD provides a robust, time-efficient, and eco-friendly platform for the determination of trace oral antidiabetic drugs in complex biological matrices.

Measurements of plasma melatonin by rapid lC-mS/mS enables insight into diurnal variation in healthy humans.

Albrethsen J, Andreasen JK, Anton J, Sennels HP, Jørgensen HL, Hannibal J, Hermann D, Wewer Albrechtsen NJ.

Scand J Clin Lab Invest

PMID:42008634

Free PMC article

Measurement of plasma melatonin is important in studies of sleep disorders and neurodegenerative diseases and is also increasingly associated with cardiometabolic diseases and cancer. There is currently an increase in the usage of melatonin in the population. However, commercially available and reliable melatonin assays are lacking. Here we present a rapid and simple LC-MS/MS-based method for plasma melatonin in a clinical laboratory. The method demonstrates a limit of detection of 5 ng/L and inter-assay imprecision p p < 0.03) but demonstrated a substantial bias. We conclude that our simple LC-MS/MS method can detect biologically relevant changes in plasma melatonin and may enable insight into circadian biology in humans. We propose that the observed differences between melatonin assays could be clarified by the distribution of reference plasma melatonin material and that additional studies are needed to fully understand the minimum circulating levels of melatonin in the daytime.

A Targeted LC-MS/MS Assay of a Health Surveillance Panel and Its Application to Chronic Kidney Disease.

Fu Q, Johnson CWC, Inker LA, Van Eyk JE, CRIC Study Investigators.

J Proteome Res

PMID:42007652

Free PMC article

Robust and reproducible assays capable of specific and quantitative monitoring of multiple biologically important proteins, among the thousands of human plasma proteins, can be used to represent the overall health of an individual and distinguish health versus disease. In this study, we established an LC-MS assay to monitor a Health Surveillance Panel (HSP), comprising 60 circulating plasma proteins selected based on their biological functions and/or disease associations. Plasma samples were prepared for proteomic analysis in an automated process and analyzed using an optimized, scheduled LC-MRM assay composed of 60 endogenous proteins monitored by 364 transitions from 117 proteotypic peptides, along with their stable isotopically labeled standard peptides. For each proteotypic peptide, a quantifier ion and at least two qualifier ions were selected based on consistent peak area ratios, a linear response for the quantifier ion, and a low limit of quantification. As proof of concept, we evaluated the performance of our HSP assay in a case-control study of progressive chronic kidney disease (CKD). Reduced plasma concentrations of alpha-2-antiplasmin, antithrombin-III, and immunoglobulin heavy constant alpha 1 correlated with CKD, with p -values <0.05. These results demonstrate that CKD-associated differences can be detected with a multiplexed HSP assay panel.

Development and validation of ratio spectra manipulation methods for the determination of etoricoxib and tramadol in binary mixtures.

Al Kamaly O, Sayedahmed M, Abdelzaher AM.

Sci Rep

PMID:42010288

Free PMC article

Two simple and selective spectrophotometric methods, ratio difference and derivative ratio, were developed and validated for the simultaneous determination of etoricoxib and tramadol in binary mixtures and pharmaceutical formulations. The methods effectively resolved the sever spectral overlap of both drugs without prior separation. In the ratio difference method, amplitude differences between 294 and 239 nm for etoricoxib and 218 and 272 nm for tramadol showed excellent linearity. In the derivative ratio method, derivative amplitudes measured at 287 nm etoricoxib, and 229 nm tramadol provided high selectivity and sensitivity. The linear ranges were 2-23 µg/mL for etoricoxib and 3-40 µg/mL for tramadol, with correlation coefficients above 0.999. Both methods achieved recoveries between 98.78 and 101.09% and precision values (%RSD) below 2%. Statistical comparison with a reported HPLC method showed no significant difference. The proposed methods are accurate, cost-effective, and supported by AGREE-based greenness assessment, making them suitable for routine quality control of etoricoxib and tramadol formulations.

Molecular strategies for heterocyclic frameworks in antidiabetic drug discovery: a vision from 2020-2024.

Tahlan S, Singh S, Dey H, Kaira M, Pandey KC.

Future Med Chem

PMID:42003351

Free PMC article

Diabetes mellitus represents a global health crisis requiring innovative therapeutic strategies beyond traditional treatments. This comprehensive review analyzes heterocyclic frameworks developed between 2020-2024 for antidiabetic drug discovery, highlighting structure-activity relationships (SAR), molecular docking insights, and therapeutic mechanisms. Key scaffold classes emerged as potent antidiabetic agents, with benzimidazoles and triazoles demonstrating dual α-amylase/α-glucosidase inhibition (IC 50 values 1.20-22.46 µg/mL), thiazolidinediones and quinazolines showing PPAR-γ agonism with improved insulin sensitivity and reduced cardiovascular risks, DPP-4 inhibitory scaffolds (pyrrolidines, pyrimidines) achieving IC 50 values as low as 0.021 µM, and SGLT2-targeting heterocycles exhibiting glucose-lowering effects with cardio-renal protection. Major findings revealed that electron-donating groups (methoxy, hydroxyl) consistently enhanced binding affinity across multiple targets, halogen substitutions (fluoro, chloro, bromo) improved metabolic stability and selectivity, hybrid molecules combining multiple pharmacophores achieved superior multi-target effects, and natural product-derived heterocycles (flavonoids, coumarins, alkaloids) showed IC 50 values 10-100× better than acarbose. Emerging frontiers include multi-agonist therapies (GLP-1/GIP, dual SGLT1/SGLT2 inhibitors), glucokinase activators for insulin-independent glucose control, microbiome-targeting agents, and AI-driven rational drug design integrating SAR, docking, and ADMET prediction. This review provides a strategic framework for developing safer, more selective antidiabetic agents through systematic exploitation of heterocyclic chemistry, advancing toward personalized diabetes management.